Chlorproguanil/dapsone
From Wikipedia, the free encyclopedia
(Redirected from Lapdap)
Chlorproguanil/dapsone (sold commercially as Lapdap) was a fixed dose antimalarial combination containing chlorproguanil and dapsone,[1] which act synergystically against malaria. The drug was withdrawn in 2008 following increasing evidence of toxicity in the form of haemolysis occurring in patients with G6PD deficiency[2].
[edit] References
- ^ Lang T, Greenwood B (March 2003). "The development of Lapdap, an affordable new treatment for malaria". Lancet Infect Dis 3 (3): 162–8. doi:10.1016/S1473-3099(03)00547-4. PMID 12614733. http://linkinghub.elsevier.com/retrieve/pii/S1473309903005474.
- ^ Luzzatto, L. (2010). "The rise and fall of the antimalarial Lapdap: A lesson in pharmacogenetics". The Lancet 376 (9742): 739–741. doi:10.1016/S0140-6736(10)60396-0. PMID 20599264.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
